8-methyl-cipro | 119914-71-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 8-methyl-cipro
• 英文别名: 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid；7-(1-Piperazinyl)-1-cyclopropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid；1-cyclopropyl-6-fluoro-5-methyl-7-(1-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid；1-cyclopropyl-6-fluoro-5-methyl-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
• CAS: 119914-71-5
• 化学式: C₁₈H₂₀FN₃O₃
• 分子量: 345.374
• InChiKey: SCKJAQPJHWGXRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  72.9
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  8-methyl-cipro 、 乙酸酐 、 盐酸 在 resultant product 、 二氯甲烷 、 magnesium sulfate 、 乙醇 作用下， 以 sodium hydroxide 为溶剂， 以to give 7-(4-acetyl-1-piperazinyl)-1 -cyclopropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid (29 mg)的产率得到7-(4-acetyl-1-piperazinyl)-1-cyclopropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  Benzoheterocyclic compounds

  摘要：

  化合物的化学式为：##STR1## 其中，R.sup.1为环丙基，可具有1至3个烷基和卤素的取代基；苯基，可被1至3个烷氧基，卤素和羟基的取代基所取代；烷基，可被卤素，烷酰氧或羟基所取代；烯基；或噻吩基，R.sup.2为5至9个成员的饱和或不饱和杂环环，可被取代，R.sup.3为烷基，R为氢或烷基，X为卤素，以及其药学上可接受的盐，这些化合物具有出色的抗微生物活性，因此可用作抗微生物剂，以及含有该化合物作为活性成分的制药组合物。

  公开号：

  US05563138A1
• 作为产物：
  描述：

  ethyl 2-(2-methyl-3,4,6-trifluorobenzoyl)-3-cyclopropylaminoacrylate 生成 8-methyl-cipro
  参考文献：
  名称：

  DOMAGALA, JOHN M.;HAGEN, SUSAN E.;KIELY, JOHN S.

  摘要：

  DOI：

文献信息

• Antibacterial agents
  申请人：Warner-Lambert Company

  公开号：US04920120A1

  公开（公告）日：1990-04-24

  Novel naphthyridine-, and quinolinecarboxylic acids as antibacterial agents are described as well as methods for their manufacture, formulation, and use in treating bacterial infections including the description of certain novel intermediates used in the manufacture of the antibacterial agents.

  描述了新型萘啶基和喹啉基羧酸作为抗菌剂的小说，以及它们的制造、配方和用于治疗细菌感染的方法，包括用于制造抗菌剂的某些新型中间体的描述。
• Intermediates for anti-microbial quinolone carboxylic acids
  申请人：Otsuka Pharmaceutical Company, Limited

  公开号：US05811576A1

  公开（公告）日：1998-09-22

  Novel 4-oxoquinoline-3-carboxylic acid compounds of the formula: ##STR1## wherein R.sup.1 is cyclopropyl which may have 1 to 3 substituents of alkyl and halogen; phenyl which may be substituted by 1 to 3 substituents of alkoxy, halogen and OH; alkyl which may be substituted by halogen, alkanoyloxy or OH; alkenyl; or thienyl, R.sup.2 is 5- to 9-membered saturated or unsaturated heterocyclic ring which may be substituted, R.sup.3 is alkyl, R is H or alkyl, and X is halogen, and pharmaceutically acceptable salts thereof, said compounds having excellent antimicrobial activity and hence being useful as an antimicrobial agent, and a pharmaceutical composition containing said compound as an active ingredient.

  公式：##STR1##其中R1是环丙基，可以有1至3个烷基和卤素的取代基；苯基，可以被1至3个烷氧基，卤素和羟基的取代基所取代；烷基，可以被卤素，烷酰氧基或羟基的取代基所取代；烯基；或噻吩基，R2是5至9个成员的饱和或不饱和杂环环，可以被取代，R3是烷基，R是氢或烷基，X是卤素，以及其药学上可接受的盐，这些化合物具有优异的抗微生物活性，因此可用作抗微生物剂，以及含有该化合物作为活性成分的制药组合物。
• Novel quinoline derivatives, processes for preparation thereof and antibacterial agent containing them
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：EP0319906A2

  公开（公告）日：1989-06-14

  1-Substituted-6-fluoro-5-methyl-7-(piperazinyl or pyrrolidinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acids (I) and processes for preparation thereof. The acids are used for treatment of a bacterial infectious desease.

  1-取代-6-氟-5-甲基-7-(哌嗪基或吡咯烷基)-1,4-二氢-4-氧代喹啉-3-羧酸 (I) 及其制备方法。这些酸可用于治疗细菌性传染病。
• Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids
  作者：Susan E. Hagen、John M. Domagala、Carl L. Heifetz、Judith Johnson

  DOI：10.1021/jm00107a040

  日期：1991.3

  A series of 5-alkyl-1,7,8-trisubstituted-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids was prepared and evaluated for in vitro and in vivo antibacterial activity. When compared to the 5-hydrogen analogues, the presence of the 5-methyl group enhanced in vitro potency for those compounds containing a cyclopropyl moiety at N1 but decreased potency for those containing an ethyl group at N1. Replacing the 5-methyl with a 5-ethyl significantly reduced the efficacy. In general, the 5-methyl and 5-hydrogen analogues were equipotent in vivo. Several of the 5-methyl-1-cyclopropylquinolones displayed excellent in vitro and in vivo activity, warranting further development.
• 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0287951B1

  公开（公告）日：1996-07-03